Proteoform Characterization of HIV-1 Broadly Neutralizing Antibody PGT 121.414.LS Product Through Middle-Up and Bottom-Up Proteomics for Clinical Support
{{output}}
Broadly neutralizing antibody (bNAb) therapies are under development for the prevention and treatment of HIV-1 infection as an alternative to conventional antiretroviral therapy because of their potential for sustained passive immunotherapy. Currently, bNAbs t... ...
